ProCE Banner Activity


Improving the Identification and Management of Advanced Cutaneous Squamous Cell Carcinoma

PCE On Demand Live Presentation

Although most patients with cutaneous squamous cell carcinoma (cSCC) are diagnosed early in their disease course when curative treatment is possible, those experiencing recurrence and metastasis historically faced a poor prognosis. The advent of immune checkpoint inhibitors (ICIs) has improved survival in patients with advanced cSCC. In this activity, a skin cancer specialist discusses the signs and symptoms of advanced cSCC, guidance and supporting evidence for ICIs, and best practices to identify and manage immune-related adverse events (irAEs).

Physician Assistants: maximum of 1.00 hours of AAPA Category 1 CME credits Registered Nurses: 1.00 Nursing contact hours, includes 1.00 hour of pharmacology credit

Released: September 22, 2022

Expiration: September 21, 2023

No longer available for credit.



Nikhil I. Khushalani

Nikhil I. Khushalani, MD

Senior Member and Vice Chair
Department of Cutaneous Oncology
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida

Kathleen Madden

Kathleen Madden, MSN, ANP-BC, AOCNP

Melanoma Program
NYU Langone Perlmutter Cancer Center
New York, NY


This activity is supported by an educational grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

Provided by

ProCE Banner


Regeneron Pharmaceuticals, Inc.


Target Audience

Oncology NPs, PAs, and nurses

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Explain factors to consider in the identification of advanced cSCC

  • Integrate ICIs into treatment plans for advanced cSCC based on guideline recommendations and clinical trial data

  • Use recommended strategies to identify and manage irAEs in the treatment of advanced cSCC


All faculty and planners participating in continuing education activities sponsored by Practicing Clinicians Exchange (PCE) are required to disclose all financial relationships with ineligible companies. All relevant conflicts of interest are thoroughly vetted and mitigated according to PCE policy. In addition, all faculty are required to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and Planning Committee have been advised that this activity must be free from commercial bias and based upon all available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.

Nikhil I. Khushalani, MD: consultant/advisor: Array BioPharma, AstraZeneca, Bristol-Myers Squibb, Castle Biosciences, Genzyme, Immunocore, Incyte, Instil Bio, Iovance Biotherapeutics, Jounce Therapeutics, Merck, Nektar, Novartis, Pfizer, Regeneron; research support (paid to institution): Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Huya Bioscience International, Merck, Novartis, Regeneron, Replimune; individual publicly traded stocks and stock options: Amarin, Asensus Surgical, Bellicum Pharmaceuticals; other: Bristol-Myers Squibb, Celgene, Nektar, Regeneron, Replimune.

Kathleen Madden, FNP, MSN, AOCNP, APHN: consultant/advisor/speaker: Novartis.

None of the members of the Planning Committee or PCE staff have any relevant financial relationships to disclose, except Kathleen Madden, FNP, MSN, AOCNP, APHN, as noted above.

Instructions for Credit

Participants wishing to earn CE/CME credit must:

  1. View the content in its entirety
  2. Relate the content material to the learning objectives
  3. Complete evaluation form

The estimated time to complete this activity is 1.00 hour.

Release date: September 22, 2022
Expiration date: September 21, 2023


On-demand webcast


The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.



Joint Accreditation Statement

Joint AccreditationIn support of improving patient care, Practicing Clinicians Exchange is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

ANCC Credit Designation

NP course advisor: Kathleen Madden, FNP, MSN, AOCNP, APHN, Perlmutter Cancer Center, New York, New York

Nursing contact hours: 1.00, which includes 1.00 hours of pharmacology credit

AAPA Credit Designation

Joint AccreditationPracticing Clinicians Exchange has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME credits. Approval is valid until September 21, 2023. PAs should only claim credit commensurate with the extent of their participation.

PA course advisor: Jessica Garner, DMSc, PA-C, University of the Pacific, Sacramento, California

IPCE Credit Designation
IPCEThis activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credits for learning and change.

Additional Information

Program Medium

This program has been made available online.